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Abstract This overview addresses homocysteine and folate
metabolism. Its functions and complexity are described,
leading to explanations why disturbed homocysteine and
folate metabolism is implicated in many different diseases,
including congenital birth defects like congenital heart
disease, cleft lip and palate, late pregnancy complications,
different kinds of neurodegenerative and psychiatric
diseases, osteoporosis and cancer. In addition, the inborn
errors leading to hyperhomocysteinemia and homocystinu-
ria are described. These extreme human hyperhomocystei-
nemia models provide knowledge about which part of the
homocysteine and folate pathways are linked to which
disease. For example, the very high risk for arterial and
venous occlusive disease in patients with severe hyper-
homocysteinemia irrespective of the location of the defect
in remethylation or transsulphuration indicates that
homocysteine itself or one of its “direct” derivatives is
considered toxic for the cardiovascular system. Finally,
common diseases associated with elevated homocysteine
are discussed with the focus on cardiovascular disease and
neural tube defects.
Homocysteine and folate metabolism
Homocysteine is an amino acid not used in protein
synthesis. Its role is to serve as an intermediate in
methionine metabolism. Homocysteine itself is located at
a branch-point of metabolic pathways: either it is irrevers-
ibly degraded via the transsulphuration pathway to cysteine
or it is remethylated back to methionine (Fig. 1).
Transmethylation
Methionine adenosyltransferase (MAT) catalyzes the biosyn-
thesis of S-adenosylmethionine (AdoMet) from methionine
and ATP (Mudd and Cantoni 1958). MAT is encoded by two
genes that display a tissue-specific expression pattern.
MAT1A encodes MAT I/III and is only expressed in adult
liver, whereas MAT2A-expressing MAT II is present in
almost all tissues (Kotb et al. 1997; Mato et al. 1997).
AdoMet donates a methyl group to, for example, DNA,
RNA, proteins and neurotransmitters. Over 100 different
methyltransferases may exist. Each of these reactions
produces S-adenosylhomocysteine (AdoHcy) which is a
potent inhibitor of most methyltransferases. AdoHcy hydro-
lase (SAHH) hydrolyzes AdoHcy to adenosine and homo-
cysteine. Because the equilibrium of SAHH favors AdoHcy
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formation, both homocysteine and adenosine need to be
metabolized or transported out of the cell to prevent AdoHcy
accumulation.
Remethylation
Homocysteine remethylation to methionine is catalyzed
by the methionine synthase (MTR) enzyme (Li et al.
1996) and links the folate cycle with homocysteine
metabolism (Fig. 1). MTR requires cobalamin (Cbl) as a
cofactor, and the resulting complex, Cbl(I)MTR, binds the
methyl group of 5-methyTHF to form methylcbl(III)MTR.
Upon transfer of the methyl group to homocysteine, Cbl(I)
MTR is reformed, which can accept another methyl group
from 5-methyltetrahydrofolate (5-methylTHF). Cob(I)
alamin can also be oxidized to cob(II)alamin, which
results in an inactive Cbl(II)MTR complex. Methionine
synthase reductase (MTRR) reactivates the Cbl(II)MTR
complex by reductive methylation, using AdoMet as a
methyl donor (Leclerc et al. 1998).
Whereas the MTR enzyme is ubiquitously expressed,
another homocysteine remethylation system, the betaine-
homocysteine methyltransferase (BHMT), is mainly
expressed in the liver and kidneys (Sunden et al. 1997).
Transsulphuration
The homocysteine molecule is retained during remethyla-
tion and transmethylation reactions, but in the transsulphu-
ration pathway homocysteine is irreversibly degraded to
cysteine. Transsulphuration is facilitated by the action of
two vitamin B6-dependent enzymes: cystathionine β-
synthase (CBS) and cystathionine γ-lyase (CTH) (Fig. 1).
CBS catalyzes the condensation of homocysteine and serine
to cystathionine and CTH subsequently catalyzes the
hydrolysis of cystathionine to cysteine and α-ketobutyrate.
Human CBS is expressed in liver, kidneys, muscle, brain
and ovary and also during early embryogenesis in the
neural and cardiac systems (Quere et al. 1999). Apart from
its role in protein synthesis, cysteine is a precursor of
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Fig. 1 Schematic representation of the folate cycles and homocysteine
metabolism. AdoHcy S-adenosylhomocysteine, AdoMet S-
adenosylmethionine, AICAR 5-aminoimidazole-4-carboxamide ribonu-
cleotode, SAHH S-adenosylhomocysteine hydrolase, ATP adenosine
triphosphate, BHMT betaine-homocysteine methyltransferase, CBS
cystathionine β-synthase, CTH cystathionine γ-lyase, DHF dihydrofo-
late, DHFR dihydrofolate reductase, dUMP deoxyuridine monophos-
phate, dTMP deoxythymidine monophosphate, FAICAR formyl-AICAR,
MAT methionine-adenosyltransferase, MTHFD methylenetetrahydrofo-
late dehydrogenase / methenyltetrahydrofolate cyclohydrolase / formyl-
tetrahydrofolate synthetase, MTHFR methylenetetrahydrofolate
reductase, MTR methionine synthase, MTRR methionine synthase
reductase, SHMT serine-hydroxymethyltransferase, THF tetrahydrofo-
late, TYMS thymidylate synthase
76 J Inherit Metab Dis (2011) 34:75–81
glutathione, a strong antioxidant and an essential compound
in detoxification of many xenobiotics.
Regulation
In most tissues, homocysteine is either remethylated via
methionine synthase or exported out of the cell. The liver
is the main organ of degradation of excess methionine
and in maintaining homocysteine at adequate levels via
an unique set of enzymes, including MAT I/III, CBS,
CTH, BHMT, GNMT (glycine N-methyltransferase). In
contrast to MAT II, MAT I/III has a high Km. This
produces that in the liver high methionine results in
increased AdoMet. One main regulatory mechanism is
that high levels of AdoMet inhibit MTHFR and activate
CBS activity, respectively (Finkelstein 2007). Methionine
excess thus results via the higher levels of AdoMet in
homocysteine degradation via the transsulphuration path-
way. Conversely, if methionine levels are low, for example
during fasting, the low AdoMet levels will not activate
CBS nor inhibit MTHFR, resulting in conservation of
homocysteine via remethylation back to methionine.
Folate cycles
Intracellularly, 5-methylTHF functions as a methyl donor
for homocysteine remethylation (Blom et al. 2006). The
resulting THF can directly be converted into 5,10-methyl-
eneTHF by the action of serine hydroxymethyltransferase
(SHMT). SHMT is a vitamin B6-dependent enzyme that
uses serine as a one-carbon donor. In humans, SHMT has a
cytosolic as well as a mitochondrial isoform (Garrow et al.
1993). Conversion of THF into 5,10-methyleneTHF, via
10-formylTHF and 5,10-methenylTHF, is catalyzed by the
trifunctional enzyme methylenetetrahydrofolate dehydroge-
nase (MTHFD1) that has formyltetrahydrofolate synthetase,
methenyltetrahydrofolate cyclohydrolase and methylenete-
trahydrofolate dehydrogenase activities (Hum et al. 1988).
The 10-formylTHF can donate one-carbon groups for
purines biosynthesis, whereas 5,10-methylenetetrahydro-
folate can be used as a cofactor for the conversion of
dUMP into dTMP. The latter reaction is catalyzed by the
thymidylate synthase (TYMS) enzyme and produces
dihydrofolate (DHF), which requires subsequent reduc-
tion back to THF by the action of dihydrofolate
reductase (DHFR). In addition to being a cosubstrate
for dTMP synthesis, 5,10-methyleneTHF can also be
reduced to 5-methylTHF by the riboflavin (vitamin B2)-
dependent enzyme methylenetetrahydrofolate reductase
(MTHFR), which competes for 5,10-methyleneTHF with
TYMS. The function of the MTHFR enzyme is of great
importance for the regulation of available 5-methylTHF
for homocysteine remethylation.
Folate uptake and transport
The water-soluble B-vitamin folate is an essential vitamin
for humans and is obtained from the diet, especially from
fruits and vegetables. According to chemical nomenclature,
the difference between folate and folic acid is just one
proton. However, the term folic acid is in general applied to
the synthetic form of this B-vitamin, which is also the most
stable form (Blom et al. 2006; Pitkin 2007). Dietary folates
predominantly exist as polyglutamates, which have to be
hydrolyzed to monoglutamates in order to be transported.
The enzyme folylpoly-γ-glutamate carboxypeptidase
(FGCP), that is anchored to the intestinal apical brush
border and is encoded by the glutamate carboxypeptidase II
(GCPII) gene, is responsible for this hydrolysis in the gut
(Fig. 2) (Chandler et al. 1991). Monoglutamylated folates
are subsequently absorbed in the duodenum and upper part
of the jejunum by the high-affinity proton-coupled folate
receptor PCFT1 (Qiu et al. 2006). 5-MethylTHF is the main
form of folate circulating in the plasma and can be
transported into the cell by means of carrier- or receptor-
mediated transport. Folate receptor α (FR-α) is a
glycosylphosphatidylinositol-linked glycoprotein with a
high affinity for the monoglutamate 5-methylTHF and
is expressed in a limited number of epithelial cells,
predominantly in the proximal tubules of the kidney, the
choroid plexus and the placenta (Wang et al. 1992; Barber
et al. 1999; Kamen and Smith 2004). The other folate
receptors, β and γ, have a much lower affinity for 5-
methylTHF than FR-α. Carrier-mediated transport occurs
via the ubiquitously expressed reduced folate carrier (RFC)
whose affinity for 5-methylTHF is also considerably lower
than that of the FR-α. The elucidation of the role of PCFT1
in cellular uptake and transport requires further research.
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Fig. 2 Schematic overview of folate uptake and transport from the
intestine, via the blood, into the cell. THF tetrahydrofolate, FR-α
folate receptor alpha, PCFT proton-coupled folate transporter, RFC1
reduced folate carrier, THF tetrahydrofolate, FGCP folylpoly-γ-
glutamate carboxypeptidase
J Inherit Metab Dis (2011) 34:75–81 77
Inborn errors of homocysteine metabolism
Severe hyperhomocysteinemia (total homocysteine >50 uM)
or homocystinuria is caused by defects in remethylation or
transsulphuration. Disturbed remethylation can be caused by
MTHFR as well as MTR deficiency due to mutations in their
genes. MTR can also be dysfunctional due to defects in
cobalamin metabolism. In MTR deficiency or dysfunction,
5-methylTHF cannot cycle through MTR resulting in 5-
methylTHF accumulation at the expense of the other folates,
hampering the synthesis of purines and thymidine. In
particular, rapidly dividing cells, such as bone marrow, will
be affected and result in megaloblastic anemia and pancyto-
penia, which are also observed in folate deficiency.
MTHFR deficiency does not limit the availability of
folates for purines and thymidine syntheses and therefore
shows no abnormalities in blood cells.
Remethylation defects result in elevated homocysteine and
decreased methionine. In the transsulfuration pathway, CBS
deficiency also results in accumulation of homocysteine, but
in contrast to remethylation defects, methionine is increased.
One typical characteristic of severe hyperhomocysteine-
mia is the wide array of different neurological presenta-
tions, ranging from schizophrenia and depression to severe
mental retardation. Another common finding is arterial and
venous occlusive disease in patients with severe hyper-
homocysteinemia, irrespective of whether the defect is in
remethylation or transsulphuration.
Interestingly, Yap et al (2001) showed a dramatic
decrease in arterial and venous occlusive disease in CBS-
deficient patients on homocysteine-lowering therapy.
Disturbed homocysteine and folate metabolism
as risk factor for vascular disease
Homocysteine and vascular disease
In 1969, Kilmer McCully (McCully 1969) recognized the
potentially harmful effects of homocysteine on the vascular
wall. In two patients with severe hyperhomocysteinemia
due to different inborn errors of homocysteine metabolism,
he found similar vascular lesions. Because severely
elevated plasma homocysteine concentration was the
only common metabolic abnormality, he postulated the
‘Homocysteine Theory’. He stated that homocysteine, or
one of its derivatives, is toxic for the vascular wall
(McCully 1969). In the years to follow, it became clear
from both retrospective and prospective studies that also
mildly elevated total homocysteine levels (of about 15 uM)
are also independently associated with an increased risk for
vascular diseases (Ueland et al. 2000). Whether or not this
association is causal is still under debate. Large intervention
trials have been performed and some are ongoing to address
this issue. Recently, a meta-analysis of the Cochrane
Database of Systematic Reviews was published (Marti-
Carvajal et al. 2009) including eight randomized controlled
trials involving 24,210 participants. Homocysteine-
lowering therapy did not reduce the risk of non-fatal or
fatal myocardial infarction, stroke, or death by any cause
[RR (risk ratio) 1.03, 95% CI 0.94 to 1.13; RR 0.89, 95%
CI 0.73 to 1.08; and RR 1.00, 95% CI 0.92 to 1.09,
respectively]. The authors concluded there is no evidence to
support the use of homocysteine-lowering therapy to
prevent cardiovascular events. Their conclusion seems valid
regarding myocardial infarction, given the small confidence
interval. However, regarding stroke with a point estimate
RR of 0.89 and a 95% confidence interval of 0.73 to 1.08,
one cannot exclude that homocysteine-lowering therapy
may relate to a RR of about 0.80 for stroke, as observed in
prospective case-control studies (Ueland et al. 2000; Wang
et al. 2007).
Homocysteine controversy
Taken together, there appears to exist an apparent homocys-
teine controversy. We observed vascular disease in inborn
errors of homocysteine metabolism, with a strong decrease in
risk on homocysteine-lowering therapy. In addition, there is
remarkable consistency in observational studies showing that
elevated homocysteine is associated with increased cardio-
vascular disease risk. In apparent contrast, however, no risk
reduction is found in homocysteine-lowering trials. These
trials are mainly based on prescription of folic acid. As
illustrated in Fig. 1, one of the main functions of folate
metabolism is to provide one-carbon building blocks for the
synthesis of purines and pyrimidine. In particular during
rapid cell growth and stress, these building blocks are
required for DNA and RNA synthesis. Thus, a side effect
of folic acid administration may be the promotion of
proliferation and inflammation, both of which are crucial
processes taking place in the atherosclerotic plaque. Intake of
high amounts of folic acid may thus be beneficial via the
homocysteine lowering, but may also be harmful via
destabilization the atherosclerotic plaque (see Smulders and
Blom in this issue for further discussion).
Disturbed homocysteine and folate metabolism
as risk factor for neural tube defects
Folic acid and neural tube defects
In 1976, Smithells et al. (1976) demonstrated decreased
levels of several micronutrients, especially folate, in serum
of women pregnant with a neural tube defect (NTD)-
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affected child during the first trimester. Subsequent small
trials in women who had a NTD-affected pregnancy
indicated that periconceptional supplementation with 0.4–
5 mg of folic acid per day decreased the recurrence risk of
NTDs about fourfold (Blom 2009). In 1991, the MRC
Vitamin Study Research group conducted a large interna-
tional double-blind placebo-controlled randomized trial in
1,817 women who had a previous NTD-affected pregnancy
and demonstrated a 72% reduction in NTD recurrence risk
for periconceptional folic acid supplementation (Vitamin
Study Research Group 1991). The protective effect of
periconceptional folic acid supplementation on NTD
occurrence risk has mainly been demonstrated in retrospec-
tive case-control studies (Blom 2009). However, a large
randomized controlled trial in Hungarian women showed
that supplementation with multivitamins including 0.8 mg
folic acid reduced the first occurrence of NTDs by 93%
(Czeizel and Dudas 1992).
The results of these studies led to the general advice
for women planning a pregnancy to take 0.4 mg of folic
acid per day at least 1 month before conception and
during the first trimester of pregnancy. Women who are
at high risk because of a previous NTD-affected
pregnancy are advised to take 4 mg of folic acid daily
in the periconceptional period (Pitkin 2007). In the years
after the endorsement of these recommendations, the
expected decline in NTD prevalence failed to occur. In
1998, the United States mandated folic acid fortification of
enriched cereal grain products was followed by a decline
of NTD rates of 20–30%.
The observation that women who use folic acid
periconceptional are at reduced risk for NTD-affected
pregnancies is one of the most promising clues to the
etiology of NTDs. In the search for mechanisms underlying
the beneficial effect of folic acid in relation to NTDs,
several mechanisms have been suggested. One mechanism
playing a possible a role in NTD etiology is methylation, as
discussed in more detail below.
Methylation
It is becoming more and more evident that, besides genetic
variation and environmental factors, epigenetic mechanisms
also play an important role in the etiology of complex
diseases (Blom et al. 2006). Since NTDs are multifactorial
in origin, epigenetic mechanisms may well be involved in
their etiology. DNA methylation, which is reprogrammed
during early embryogenesis (Reik et al. 2001), is part of the
epigenetic code and is a chief regulator of gene expression
(Dean et al. 2005), has been hypothesized to be associated
with NTDs (Blom et al. 2006).
The methylenetetrahydrofolate reductase (MTHFR) en-
zyme has a unique function in that it regulates the
availability of methyl groups for methylation reactions at
the cost of purines and pyrimidine synthesis. The 677C>T
variant in the MTHFR gene renders a less active thermo-
labile MTHFR enzyme (Frosst et al. 1995), resulting in
elevated levels of 10-formylTHF and a decreased availabil-
ity of 5-methylTHF in red blood cells (Bagley and Selhub
1998). The observations that the MTHFR 677TT genotype
decreases the availability of 5-methylTHF for methylation
(Frosst et al. 1995), results in a reduction of global DNA
methylation (Friso et al. 2002; Castro et al. 2004), and is a
genetic risk factor for NTDs (van der Put et al. 1995; Blom
et al. 2006) support the concept that DNA methylation
plays an important role in NTD etiology. The observation
that inactivation of the DNA methyltransferase DNMT3B
disrupts de novo DNA methylation, and causes multiple
developmental defects including NTDs in mice, further
supports the importance of DNA methylation (Okano et al.
1999). In addition, culturing rat embryos on low methio-
nine containing media-induced NTDs resulted in protein
hypomethylation that was specific for those proteins located
in the neural tube, indicating that protein methylation may
also play a role in proper neural tube closure (Coelho and
Klein 1990; Moephuli et al. 1997).
Using a chick embryo model, our group tested the
hypothesis that methylation is crucial for proper neural
tube closure (Afman et al. 2005). Inhibition of SAHH in
our in vitro chick embryo model resulted in inhibition of
methylation, as judged from the increased AdoHcy
concentration and a decreased AdoMet/AdoHcy ratio,
and a widening of the anterior neuropore (ANP). Compa-
rable results were obtained by inhibition of MAT.
Inhibition of MAT in cultured mouse embryos also
decreased the AdoMet/AdoHcy ratio, and these embryos
also presented with cranial closure defects (Dunlevy et al.
2006). The AdoMet/AdoHcy ratio in mothers of a NTD-
affected child has been demonstrated to be decreased
(Zhao et al. 2006). Only one study, however, has actually
examined DNA methylation status in relation to NTDs
(Al-Gazali et al. 2001). In that study, the AdoMet/AdoHcy
ratio and DNA methylation were both decreased in a
single case with trisomy 21 and spina bifida (Al-Gazali et
al. 2001). Taken together, these studies have lead to the
hypothesis that methylation is hampered in women that are
pregnant with a NTD-affected child and that folic acid
supplementation prevents NTDs by donating methyl
groups, hereby improving methylation (Blom et al. 2006).
In the future, large-scale studies in which DNA
methylation patterns of healthy newborns and those with a
NTD will be characterized and compared using array-based
approaches, which will shed more light on the association
between an impaired DNA methylation and NTD etiology
in humans and may identify new genes essential for neural
tube closure. If an impaired DNA methylation is indeed
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associated with NTD etiology, the next step will be to
examine whether folic acid supplementation of the mother
can affect DNA methylation patterns in her child.
The ultimate goal of identifying genes that are under
epigenetic control and involved in NTD etiology is the
identification of molecular pathways that are essential for
proper neural tube closure and can be manipulated and in
this way prevent NTDs.
Disturbed homocysteine and folate metabolism
as risk factor for common diseases
Given the essential roles of folate and homocysteine in
cellular metabolism via donations of one-carbon units for
purines, thymidine and methylation reactions, it is not
surprising that impaired homocysteine and folate metabo-
lism is associated not only with cardiovascular disease and
neural tube defects but with a wide range of common
diseases. These include congenital birth defects like
congenital heart disease, cleft lip and palate, late pregnancy
complications, different kinds of neurodegenerative and
psychiatric diseases, osteoporosis and cancer. Whether or
not folic acid or other means of homocysteine lowering
forms of therapy will reduce the risk of these diseases
remains a main focus of future research. Regarding
congenital defects and late pregnancy complications, the
design of a placebo-controlled intervention study is
complicated because folic acid in a daily dosage of
0.4 mg is advised to women planning a pregnancy.
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